PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor–Positive Early Breast Cancer.
The value of PAM50-based Prosigna risk of recurrence (ROR) score for predicting distant recurrence (DR) was examined in a cohort consisting of postmenopausal women with HR+ early breast cancer treated with 5 years of endocrine therapy alone. Prosigna was used to test 2740 patients, and 2558 HR+/HER2− samples were analyzed, including from 1395 node-positive patients. […]
